Treatment of latent tuberculosis infection [5] (multiple letters)

New England Journal of Medicine

Volumn 348, Issue 13, 2003, Pages 1292-1294

  Barton, Leslie L ^a   Lepage, Philippe ^b   De Rosa, Francesco G ^c   Craven, Donald E ^d   Meyer, Bernard C ^e   Jasmer, Robert M ^f   Nahid, Payam ^f   Hopewell, Philip C ^f   Blum, Lawrence D ^g  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF TURIN   (Italy)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^e KAISER PERMANENTE   (United States)

^f SAN FRANCISCO GENERAL HOSPITAL   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL TRANSMISSION; CROHN DISEASE; DRUG EFFICACY; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION CONTROL; LETTER; LIVER TOXICITY; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION; TUBERCULIN TEST; TUBERCULOSIS; ADULT; FEMALE; NOTE; DRUG ADMINISTRATION; DRUG COMBINATION; DISEASE TRANSMISSION; GOVERNMENT; GOVERNMENT REGULATION; STANDARD; UNITED STATES; UNIVERSITY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; HUMAN; ISONIAZID; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS; HUMANS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; RIFAMPIN; DISEASE TRANSMISSION; FACULTY; GOVERNMENT REGULATION; STATE GOVERNMENT; UNITED STATES; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CROHN DISEASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037468690     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200303273481318     Document Type: Letter

References (0)